You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Bausch & Lomb reported Q3 revenue of $1.375 billion, up 8%, and adjusted EBITDA of $325 million, up 34%. It raised full-year revenue guidance to $5.450 to $5.550 billion and adjusted EBITDA guidance to $1.090 to $1.140 billion.
On October 28, 2026, Nathalie Bernier resigned from Bausch + Lomb Corporation’s Board and Science and Technology Committee. The company will pay prorated cash compensation and accelerate vesting of her restricted share unit awards; the Board does not currently intend to fill the vacancy.
Bausch + Lomb reported third-quarter revenues of $1,375 million, up $94 million or 7%, and attributable net income of $32 million, versus a net loss of $28 million.
Bausch + Lomb posted third-quarter revenue of $1.375 billion, up 7%, $32 million net income and adjusted EBITDA of $325 million. It raised full-year revenue guidance to $5.450B - $5.550B and adjusted EBITDA excluding acquired IPR&D guidance to $1.090B - $1.140B.
Bausch + Lomb Corporation said Brent Saunders departed as CEO and board member effective October 12, 2026; Thomas J. Appio became interim CEO, and Saunders will receive $75.5 million. The company expects to raise full-year 2026 adjusted EBITDA guidance.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Constant Currency Revenue(Non-GAAP) non-GAAP | 1.38B | three months ended June 30, 2026 filing | — |
| Cost of goods sold as a percentage of Product sales | 37.9% | three months ended June 30, 2026 filing | — |
| Pharmaceuticals Segment Profit non-GAAP | 89M | three months ended June 30, 2026 filing | — |
| Pharmaceuticals Segment Profit Margin | 25% | three months ended June 30, 2026 filing | — |
| Surgical Segment Profit non-GAAP | 17M | three months ended June 30, 2026 filing | — |
| Surgical Segment Profit Margin | 7% | three months ended June 30, 2026 filing | — |
| Total Segment Profit non-GAAP | 335M | three months ended June 30, 2026 filing | — |
| Vision Care Segment Profit non-GAAP | 229M | three months ended June 30, 2026 filing | — |
| Vision Care Segment Profit Margin | 29% | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLCO
this stock
Bausch & Lomb Corp
|
$7.54B | +23.5% | +6.5% | — | 0.7% |
|
ISRG
Intuitive Surgical Inc
|
$153.77B | -21.7% | +20.5% | 53.8 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$59.39B | — | +8.2% | 96.5 | 3.0% |
|
MDLN
Medline Inc.
|
$51.92B | -6.0% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.61B | -6.0% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
On October 28, 2026, Nathalie Bernier resigned from Bausch + Lomb Corporation’s Board and Science and Technology Committee. The company will pay prorated cash compensation and accelerate vesting of her restricted share unit awards; the Board does not currently intend to fill the vacancy.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLCO | +5.5% | +27.9% | +33.7% | +5.5% | +23.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.9% | +29.1% | +33.2% | +5.6% | +12.9% |
